Vir Biotechnology. has been granted a patent for antibodies that target the antigenic loop region of hepatitis B surface antigen, effectively neutralizing hepatitis B and delta viruses. The patent includes specific amino acid sequences for these antibodies, which may be used in diagnosis, prevention, and treatment of hepatitis B and D. GlobalData’s report on Vir Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vir Biotechnology, Peptide pharmacophores was a key innovation area identified from patents. Vir Biotechnology's grant share as of July 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for neutralizing hepatitis b and d viruses
The granted patent US12037381B2 outlines a series of claims related to isolated antibodies and their antigen-binding fragments, specifically targeting hepatitis B and hepatitis D infections. The primary claim details antibodies that include specific amino acid sequences for complementarity-determining regions (CDRs) from both heavy and light chains, identified by various SEQ ID numbers. Additional claims expand on the structural characteristics of these antibodies, including the presence of a heavy chain variable domain (VH) and a light chain variable domain (VL) with at least 95% sequence identity to specified SEQ IDs. The patent also encompasses nucleic acid molecules encoding these antibodies, vectors for their expression, and pharmaceutical compositions that combine the antibodies with acceptable excipients.
Furthermore, the patent describes methods for treating hepatitis B and/or hepatitis D infections by administering the specified antibodies or their fragments to subjects in need. The claims specify various patient scenarios, including those with chronic hepatitis B infections, individuals who have received liver transplants, newborns, and patients undergoing hemodialysis. The treatment methods may be used in conjunction with other therapies, such as polymerase inhibitors, interferons, or checkpoint inhibitors, highlighting the potential for combination therapies in managing these viral infections. Overall, the patent presents a comprehensive approach to developing targeted antibody therapies for hepatitis B and D, with implications for both therapeutic and diagnostic applications.
To know more about GlobalData’s detailed insights on Vir Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
